platoseedplatoseed
Breakthrough medicines unlocking the biology of heme
Velorum Therapeutics is developing breakthrough medicines by unlocking the biology of heme.
Velorum Therapeutics aims to transform patient outcomes by targeting the biology of heme, a key iron-containing molecule involved in oxygen transport, energy generation, and detoxification. The company positions itself as developing transformational medicines to address diseases linked to heme synthesis, transport, and utilization, including porphyrias, cancer, and tissue injury.
The product approach centers on unlocking the biology of heme to create therapies that address diseases arising from heme synthesis or transport disruptions. The pipeline focuses on innovative therapies designed to modulate heme-related pathways to treat conditions such as porphyrias, cancer, and tissue injury, with the aim of providing new horizons for patients with unmet needs.
Who it’s for: Clinicians and researchers in hematology, oncology, and metabolic/porphyria specialties; pharmaceutical development teams and biotech partnering avenues seeking heme-targeted therapies.
Website references a pipeline and a focus on transformative medicines, with an address and contact info but no explicit funding, hiring, or traction details.
Co-Founder & CEO @ Velorum Therapeutics. Building new medicines.
Co-Founder and President @ Velorum Therapeutics. Goldwater Scholar. Working to create breakthrough medicines for devastating diseases.
We're developing a new class of cancer drugs that starve tumors by hijacking cancer metabolism.
Velorum Therapeutics develops a new class of cancer drugs that starve tumors by removing heme, a molecule cancers rely on for energy. They report mouse data and plan first-in-human trials next year, starting with lung cancer, with potential applicability to other cancers.
From the original launch (Feb 2024) — may be outdated.
Our drugs engage the immune system to fight tumors
Elevated mRNA for transformative medicines.
